$80,000 of INCYTE CORPORATION lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act."
You can find more data on corporate lobbying on Quiver Quantitative.
INCY Insider Trading Activity
INCY insiders have traded $INCY stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months:
- HERVE HOPPENOT sold 187,500 shares for an estimated $19,773,750
- MICHAEL JAMES MORRISSEY (EVP, Head of Tech. Operations) has made 0 purchases and 3 sales selling 58,331 shares for an estimated $5,675,001.
- STEVEN H STEIN (EVP & Chief Medical Officer) has made 0 purchases and 4 sales selling 43,531 shares for an estimated $4,449,228.
- PABLO J CAGNONI (President, R&D) has made 0 purchases and 2 sales selling 37,335 shares for an estimated $3,642,965.
- MOHAMED KHAIRIE ISSA (EVP, Head of US Oncology) sold 10,856 shares for an estimated $1,184,063
- PATRICK A MAYES (EVP & Chief Scientific Officer) has made 0 purchases and 2 sales selling 5,808 shares for an estimated $554,965.
- THOMAS TRAY (Principal Accounting Officer) has made 0 purchases and 2 sales selling 3,374 shares for an estimated $336,350.
- LEE HEESON (EVP, Head of Incyte Intl) sold 3,074 shares for an estimated $289,017
- SHEILA A. DENTON (EVP & General Counsel) has made 0 purchases and 2 sales selling 876 shares for an estimated $89,625.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INCY Hedge Fund Activity
We have seen 455 institutional investors add shares of INCY stock to their portfolio, and 298 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,439,622 shares (-73.8%) from their portfolio in Q4 2025, for an estimated $438,501,464
- BELLEVUE GROUP AG removed 1,435,913 shares (-99.7%) from their portfolio in Q4 2025, for an estimated $141,825,127
- PACER ADVISORS, INC. removed 1,248,642 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $123,328,370
- AQR CAPITAL MANAGEMENT LLC removed 1,203,487 shares (-15.2%) from their portfolio in Q4 2025, for an estimated $118,868,410
- MARSHALL WACE, LLP added 1,056,451 shares (+6586.4%) to their portfolio in Q4 2025, for an estimated $104,345,665
- MAN GROUP PLC removed 834,218 shares (-43.1%) from their portfolio in Q4 2025, for an estimated $82,395,711
- UBS GROUP AG removed 775,599 shares (-53.3%) from their portfolio in Q4 2025, for an estimated $76,605,913
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INCY Analyst Ratings
Wall Street analysts have issued reports on $INCY in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/11/2026
- TD Cowen issued a "Buy" rating on 01/13/2026
- Barclays issued a "Overweight" rating on 11/24/2025
- Piper Sandler issued a "Overweight" rating on 11/04/2025
- Guggenheim issued a "Buy" rating on 11/03/2025
To track analyst ratings and price targets for INCY, check out Quiver Quantitative's $INCY forecast page.
INCY Price Targets
Multiple analysts have issued price targets for $INCY recently. We have seen 15 analysts offer price targets for $INCY in the last 6 months, with a median target of $110.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $135.0 on 04/15/2026
- Ashwani Verma from UBS set a target price of $94.0 on 03/25/2026
- Faisal Khurshid from Jefferies set a target price of $94.0 on 03/16/2026
- Maneka Mirchandaney from Evercore ISI Group set a target price of $110.0 on 03/05/2026
- Etzer Darout from Barclays set a target price of $117.0 on 02/18/2026
- Stephen Willey from Stifel set a target price of $120.0 on 02/11/2026
- Derek Archila from Wells Fargo set a target price of $101.0 on 02/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
